

Benign Prostatic Hyperplasia - Pipeline Insight, 2021

<https://marketpublishers.com/r/B34FC07DCBAEEN.html>

Date: July 2021

Pages: 70

Price: US\$ 1,500.00 (Single User License)

ID: B34FC07DCBAEEN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Benign Prostatic Hyperplasia - Pipeline Insight, 2021," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Benign Prostatic Hyperplasia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Benign Prostatic Hyperplasia Understanding

Benign Prostatic Hyperplasia: Overview

Benign prostatic hyperplasia (BPH) refers to the change in the size of the prostate and not the potential symptoms that it may cause, which are usually referred to as lower urinary tract symptoms (LUTS). LUTS may be primarily irritative, obstructive, or mixed. Men with BPH may be asymptomatic, respond to lifestyle changes, or require medical or surgical therapy; symptoms are more common as men age. The symptoms of benign prostatic hyperplasia include sensation of incomplete bladder emptying, straining to void, urinary hesitancy, weak urinary stream, dysuria, nocturia, urinary frequency, and urinary urgency. Assessment of medical history of the patient and physical examination, including a digital rectal examination (DRE) and urinalysis are done for diagnosis of BPH. Further investigations, such as uroflowmetry and measuring PVR volume, should

help to confirm the presence of obstructive symptoms attributable to BPH. The two major classes of medications for BPH are alpha-adrenergic blockers and 5-alpha reductase inhibitors.

'Benign Prostatic Hyperplasia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Benign Prostatic Hyperplasia pipeline landscape is provided which includes the disease overview and Benign Prostatic Hyperplasia treatment guidelines. The assessment part of the report embraces, in depth Benign Prostatic Hyperplasia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Benign Prostatic Hyperplasia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Benign Prostatic Hyperplasia R&D. The therapies under development are focused on novel approaches to treat/improve Benign Prostatic Hyperplasia.

Benign Prostatic Hyperplasia Emerging Drugs Chapters

This segment of the Benign Prostatic Hyperplasia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Benign Prostatic Hyperplasia Emerging Drugs

Fexapotide: Nymox Pharmaceutical

Fexapotide (NX-1207) is a pro-apoptotic injectable protein and is in development for the treatment of benign prostatic hyperplasia. In May 2021, Nymox Pharmaceutical

announced that it will be filing for marketing approval of Fexapotide Triflutate for BPH before the end of the summer, on or before September 15, 2021.

AIV007: AiViva BioPharma

AIV007 is a novel formulation using company's JEL Technology designed for prolonged drug release. AIV007 targets multiple pathways including VEGFR, PDGFR, and FGFR to address neovascularization and fibrosis, and it also modulates TGF β 1 mRNA expression and TGF β 1 levels to prevent and inhibit cell proliferation. AIV007 is currently in clinical studies for neovascular macular degeneration (nAMD) treatment and in preclinical studies for benign prostatic hyperplasia (BPH), and certain solid tumors.

Further product details are provided in the report.....

Benign Prostatic Hyperplasia: Therapeutic Assessment

This segment of the report provides insights about the different Benign Prostatic Hyperplasia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Benign Prostatic Hyperplasia

There are approx. 12+ key companies which are developing the therapies for Benign Prostatic Hyperplasia. The companies which have their Benign Prostatic Hyperplasia drug candidates in the most advanced stage, i.e. Preregistration include, Nymox Pharmaceutical.

Phases

DelveInsight's report covers around 12+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Benign Prostatic Hyperplasia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Benign Prostatic Hyperplasia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Benign Prostatic Hyperplasia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Benign Prostatic Hyperplasia drugs.

Benign Prostatic Hyperplasia Report Insights

- Benign Prostatic Hyperplasia Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Benign Prostatic Hyperplasia Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Benign Prostatic Hyperplasia drugs?

How many Benign Prostatic Hyperplasia drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Benign Prostatic Hyperplasia?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Benign Prostatic Hyperplasia therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Benign Prostatic Hyperplasia and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Nymox Pharmaceutical

ASKA Pharmaceutical

Otsuka Pharmaceutical

Aiviva BioPharma

Veru Helathcare

Boryung Pharmaceutical

KAEL-GemVax

Dong-A ST/Mezzion

Key Products

Fexapotide

AKP009

Tolvaptan

AIV007

Tamsulosin delayed-release

BR9006

Tertomotide

Udenafil

Contents

Introduction

Executive Summary

Benign Prostatic Hyperplasia: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Benign Prostatic Hyperplasia – DelveInsight's Analytical Perspective

Late Stage Products (Preregistration)

Comparative Analysis

Fexapotide: Nymox Pharmaceutical

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Tolvaptan: Otsuka Pharmaceutical

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Preclinical/Discovery Stage Products
 Comparative Analysis
Lenvatinib: AiViva BioPharma
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
 Comparative Analysis
Benign Prostatic Hyperplasia Key Companies
Benign Prostatic Hyperplasia Key Products
Benign Prostatic Hyperplasia- Unmet Needs
Benign Prostatic Hyperplasia- Market Drivers and Barriers
Benign Prostatic Hyperplasia- Future Perspectives and Conclusion
Benign Prostatic Hyperplasia Analyst Views
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Benign Prostatic Hyperplasia
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Benign Prostatic Hyperplasia
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Benign Prostatic Hyperplasia - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/B34FC07DCBAEEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B34FC07DCBAEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970